

1 **Drug-Eluting or Bare-Metal Stents For Percutaneous Coronary Intervention: A Systematic Review**
2 **and Individual Patient Data Meta-Analysis of Randomized Clinical Trials**

3
4 *Raffaele Piccolo, Kaare H. Bona, Orestis Efthimiou, Olivier Varenne, Andrea Baldo, Philip Urban, Christoph*
5 *Kaiser, Wouter Remkes, Lorenz Räber, Adam de Belder, Arnoud W.J. van't Hof, Goran Stankovic, Pedro A.*
6 *Lemos, Tom Wilsgaard, Jörg Reifart, Alfredo E. Rodriguez, Expedito E. Ribeiro, Patrick W.J.C. Serruys, Alex*
7 *Abizaid, Manel Sabaté, Robert A. Byrne, Jose M. de la Torre Hernandez, William Wijns, Peter Jüni, Stephan*
8 *Windecker, and Marco Valgimigli on behalf of the Coronary Stent Trialists' (CST) Collaboration*

9
10 **Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy (Dr.**
11 **R.Piccolo. MD, PhD); Department of Community Medicine, University of Tromsø-The Arctic University**
12 **of Norway, Tromsø, Norway (Prof K.H. Bona, MD, PhD, Dr. T. Wilsgaard, MSc, PhD); Institute of Social**
13 **and Preventive Medicine, University of Bern, Bern, Switzerland (Dr. O. Efthimiou, PhD); Department of**
14 **Cardiology, Hôpital Cochin, AP-HP, Paris, France; Université Paris Descartes, Faculté de Médecine,**
15 **Paris, France (Dr. O. Varenne, MD PhD.); Department of Cardiology, Bern University Hospital,**
16 **University of Bern, Bern, Switzerland (Dr. A. Baldo, MD, Dr. L. Räber, MD, PhD, Prof S. Windecker, MD,**
17 **Prof. M.Valgimigli, MD, PhD); Hôpital de la Tour, Geneva, Switzerland (Dr. P.Urban, MD); Department of**
18 **Cardiology. University Hospital Basel, University of Basel, Basel, Switzerland (Prof. C. Kaiser, MD);**
19 **Department of Cardiology, Sussex Cardiac Centre, Brighton and Sussex University Hospitals,**
20 **Brighton, United Kingdom (Prof. A. de Belder, MD); Department of Cardiology, Isala Heart Centre,**
21 **Zwolle, the Netherlands (Dr. W. Remkes, MD, Prof. A.W.J. van't Hof, MD, PhD), Department of**
22 **Cardiology, Maastricht University Medical Center, the Netherlands, Department of Cardiology,**
23 **Zuyderland Medical Center Heerlen, the Netherlands (Prof. A.W.J. van't Hof, MD, PhD); Department of**
24 **Cardiology, Clinical Center of Serbia, University of Belgrade, Serbia (Dr. G. Stankovic, MD, PhD); Heart**
25 **Institute (InCor), University of São Paulo Medical School, Brazil (Dr. P. A. Lemos, MD, PhD);**
26 **Department of Cardiology, Kerckhoff Klinik, Bad Nauheim, Germany (Dr. J. Reifart, MD); Cardiac Unit,**
27 **Cardiology Fellow Training Program, Otamendi Hospital, Buenos Aires School of Medicine, Buenos**
28 **Aires, Argentina (Prof. A. E. Rodrieguez, MD, PhD); Instituto do Coração (INCOR), São Paulo, Brazil**
29 **(Prof. E.E. Ribeiro, MD); International Centre for Circulatory Health, National Heart and Lung Institute,**
30 **Imperial College, London, London, United Kingdom (Prof. P. W. J. C. Serruys, MD, PhD); Department**
31 **of Invasive Cardiology, Institute Dante Pazzanese of Cardiology, São Paulo, Brazil (Dr. A. Abizaid,**

1 MD); **Cardiology Department, Cardiovascular Institute (ICCV), Hospital Clínic, IDIBAPS, University of**
2 **Barcelona, Barcelona, Spain** (Prof. M. Sabaté, MD, PhD); **Deutsches Herzzentrum München,**
3 **Technische Universität München and DZHK (German Centre for Cardiovascular Research), partner**
4 **site Munich Heart Alliance, both Munich, Germany** (Dr. R. A. Byrne, MB, BCh, PhD); **Hospital Marqués**
5 **de Valdecilla, Santander, Spain** (Dr. J.M. de la Torre Hernandez, MD, PhD); **The Lambe Institute for**
6 **Translational Medicine and Curam, University Road, National University of Ireland Galway, Galway,**
7 **Ireland** (Prof. W. Wijns, MD, PhD); **Applied Health Research Centre of the Li Ka Shing Knowledge**
8 **Institute, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario,**
9 **Canada** (Prof. P. Jüni, MD, PhD).

10
11

12 **Funding:** There was no industry involvement in the design, analysis or funding of this study. This study was
13 funded by institutional support of the Department of Cardiology at Bern University Hospital, Bern,
14 Switzerland

15

16 *Brief title: DES vs. BMS for PCI.*

17

18 *Total word count: Abstract: 299*

19

20 Address for correspondence: Prof. Marco Valgimigli, Department of Cardiology, Bern University Hospital
21 University of Bern, 3010 Bern, Switzerland, Phone: (+41 31) 632 4714, Fax: (+41 31) 632 11 31
22 Email: marco.valgimigli@insel.ch

Summary

Background New-generation drug-eluting stents (DES) have been mostly investigated by means of head-to-head non-inferiority trials, which typically showed comparable efficacy and greater safety as compared with early-generation DES. Evidence related to new-generation DES versus bare-metal stents (BMS) is more limited, and there remain uncertainties on their comparative safety profile.

Methods We performed an individual patient data (IPD) meta-analysis of randomized trials comparing new-generation DES with BMS among patients undergoing percutaneous coronary intervention. The protocol of the study was registered in PROSPERO (CRD42017060520). The primary outcome was the composite of cardiac death or myocardial infarction. Data were pooled in a one-stage random effects meta-analysis and examined at maximum follow-up and with 1-year landmark. Risk estimates are reported as hazard ratio (HR) with 95% confidence intervals (95%CI).

Findings We obtained IPD data from 20 randomized trials including a total of 26,616 patients, with 3.2±1.8 years mean follow-up. The primary outcome occurred in fewer patients in the DES group than in the BMS group (HR 0.84, 95%CI 0.78 to 0.90, P<0.001) owing to lower risk of myocardial infarction (HR 0.79, 95%CI 0.71 to 0.88, P<0.001) and weaker evidence for a possible cardiac mortality benefit (HR 0.89, 95%CI 0.78 to 1.01, P=0.075). All-cause death was unaffected (HR with DES, 0.96, 95%CI 0.88 to 1.05, P=0.358), but DES reduced the risk of definite stent thrombosis (HR 0.63, 95%CI 0.50 to 0.80, P<0.001) and target-vessel revascularization (HR 0.55, 95%CI 0.50 to 0.60, P<0.001). There was evidence for a time-dependent treatment effect, with DES being associated with lower risks of the primary outcome during the first year followed by a null effect in the subsequent years.

Interpretation New-generation DES instead of BMS were associated with sustained reduction of cardiac death or myocardial infarction owing to lower event rates within the first year without offsetting effects thereafter.

Key words: Drug-eluting stent – Bare metal stents — Percutaneous coronary intervention — Meta-analysis

1 **Introduction**

2 Percutaneous coronary intervention (PCI) for the treatment of obstructive coronary artery disease is the most
3 commonly performed cardiovascular procedure and one of the most frequent interventions in medicine. By
4 using antiproliferative agents, drug-eluting stents (DES) reduce restenosis by inhibiting neointimal
5 hyperplasia and have marked an important milestone in the field of myocardial revascularization, allowing
6 PCI to be adopted in an increasing number of patient and lesion subsets.¹

7 Early-generation DES, releasing sirolimus or paclitaxel were associated with similar risks of death and
8 myocardial infarction (MI), but with an increased, albeit small, risk of stent thrombosis beyond 1 year after
9 stent implantation as compared with bare-metal stents.^{2,3} Since then, new platforms for DES that are aimed
10 at improving safety and efficacy have been developed.

11 Contemporary DES reduce the risk of stent thrombosis as opposed to earlier iterations and retain greater
12 efficacy than bare-metal stents (BMS) in limiting the risk of repeat revascularization.⁴ In addition, randomized
13 evidence mainly derived from network meta-analyses suggests that new-generation DES might also
14 decrease the risk of stent thrombosis compared with BMS.^{5,6} However, new-generation DES have been
15 mostly investigated by means of head-to-head non-inferiority trials in comparison with early-generation DES
16 and it remains unclear whether they improve other outcomes than stent thrombosis and repeat
17 revascularization procedures as compared with BMS, which continue to be employed in a sizable proportion
18 of patients worldwide.⁷

19

20 **Methods**

21 The protocol was developed according to the guidelines of the Preferred Reporting Items for a Systematic
22 Review and Meta-analysis of Individual Participant Data (PRISMA-IPD) Development Group⁸ and was
23 registered online in the PROSPERO international prospective register of systematic reviews
24 (http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017060520).

25

26 **Search strategy and eligibility criteria**

27 We performed an IPD meta-analysis of randomized trials that compared new-generation DES versus BMS
28 among patients with coronary artery disease undergoing PCI. We used a broad definition for new-generation
29 DES that were considered as any DES subsequent to the Cypher sirolimus-eluting stent (Cordis, Miami
30 Lakes, Florida, USA) and the Taxus paclitaxel-eluting stent (Boston Scientific, Natick, Massachusetts, USA).
31 In order to qualify, trials had to use new-generation DES in at least 90% of patients randomized to the

1 experimental arm. Two investigators (RP and AB) determined trial eligibility criteria and a third investigator
2 (MV) was involved in case of disagreement. Randomized trials were identified by a systematic search in
3 PubMed, EMBASE, and three websites (www.tctmd.com, www.escardio.org, www.cardiosource.com).
4 Reference lists of retrieved articles were hand searched. There were no language restrictions. A search
5 algorithm (last updated on December 19th, 2017) is provided in the web-appendix.

6

7 **Data collection and quality assessment**

8 We contacted the principal investigators of the eligible trials, requesting IPD to be provided in an anonymized
9 electronic dataset (web appendix). Data for five randomized trials were already available from a previous
10 study.⁹ Data were checked for completeness and consistency, and were compared with the results of the
11 original publications. The principal investigators of the included trials were contacted in case of missing data
12 or when queries emerged during the integrity checks. Once queries had been resolved, the clean data were
13 uploaded to the main study dataset. Two investigators (RP, AB) independently assessed the quality of
14 included trials using the Cochrane Collaboration's tool for assessing risk of bias. Disagreements were
15 resolved first by discussion and then by consulting a third author (MV) for arbitration. Each trial had been
16 approved by its local medical ethics committee, and all patients had provided written informed consent.

17

18 **Outcomes**

19 The prespecified primary outcome in this meta-analysis was the composite of cardiac death or myocardial
20 infarction. Secondary outcomes were all-cause death, cardiac death, MI, target-vessel revascularization
21 (TVR), and definite stent thrombosis. Outcomes were analyzed at the longest available follow-up in the
22 primary analysis, as well as at 5-year follow-up and with a 30-day and 1-year landmark.

23

24 **Data analysis**

25 Continuous variables were summarized by their means and standard deviation across all included patients.
26 The two treatment groups were compared with ANOVA statistic stratified by trial. Categorical variables were
27 summarized by the corresponding counts and percentages, and were compared with the Cochran-Mantel-
28 Haenszel statistic stratified by trial.

29 All outcomes were analyzed using time-to-event analysis. We first summarized the data using unadjusted
30 Kaplan-Meier estimates at the longest available follow-up. We then performed a series of IPD random-
31 effects meta-analyses. All analyses were performed according to the intention-to-treat principle and utilized

1 IPD. For all analyses, the pooled risk estimates were expressed as hazard ratios (HRs) with 95% confidence
2 intervals (CIs). For the primary analysis, we used a one-stage IPD meta-analysis model.¹⁰ In this approach,
3 we synthesized IPD from all trials simultaneously while preserving the randomization of the original trials. In
4 sensitivity analyses we used a two-stage approach and analyzed the data from each study independently,
5 using a Cox-regression model and then combined the study-specific logarithms of the HR and the
6 corresponding standard errors at the second stage, using the DerSimonian-Laird random effects model with
7 Hartung-Knapp variance estimator.¹¹ In a further analysis, we performed a one-stage fixed-effect analysis by
8 using Cox-regression model stratified by trial. For the one-stage IPD meta-analysis we assessed the extend
9 of heterogeneity by assessing the estimated value of τ , i.e. the standard deviation of random effects; for the
10 two-stage IPD meta-analysis we also calculated visually inspected the forest plots and calculated the I^2
11 statistic.¹² To account for τ in the uncertainty around the pooled risk estimates, we also calculated 95%
12 prediction intervals for hazard ratios.¹³ The number needed to treat for benefit (NNTB) was derived from the
13 inverse of the absolute risk reduction. We performed a landmark analysis by setting as a landmark at 1 year
14 and derived the p value of the interaction for effect modification by period (**web-appendix**).¹⁴

15 Possible sources of heterogeneity in treatment effect were explored by assessing the effect of prespecified
16 variables on the primary outcome using a one-stage IPD meta-analysis model with treatment-covariate
17 interactions.¹⁵ The model is described in the **web-appendix**. We fitted a separate model for each covariate.
18 The prespecified variables were: age (analyzed as a continuous variable), gender, diabetes, clinical
19 presentation at the time of PCI, overlapping stent, multivessel disease, number of implanted stents, PCI on
20 the left anterior descending artery, mean stent diameter, use of glycoprotein IIb/IIIa receptor inhibitors, use of
21 newer P2Y₁₂ receptor inhibitors. In a sensitivity analysis we also fitted an IPD model that separated the
22 within- and across-trial treatment-covariate interactions, so as to avoid ecological bias.¹⁵

23 All P values we calculated were based on 2-sided tests. A P-value less than 0.05 was considered significant
24 for all analyses. We used Stata Statistical Software, release 14 (StataCorp LP, College Station, Texas) and
25 R version 3.2.1 for all statistical analyses.

26

27 **Additional analyses**

28 We conducted sensitivity analyses excluding patients who underwent PCI with implantation of early-
29 generation DES (115 patients had received the Cypher DES and 90 patients had received Taxus DES) and
30 patients who received thick-struts BMS (defined as a strut thickness >100 μm). A landmark analysis with two
31 timepoints (30 days and 365 days) was also performed in order to further appraise the differential

1 contribution of very early stent failure events, mainly thrombotic in nature, as opposed to those occurring in
2 between 30 days and 1 year, mostly related to an abnormal healing process leading to neointimal
3 hyperplasia (**web-appendix**).

4

5 **Role of the funding source**

6 There was no industry involvement in the design, analysis or funding of this study. This study was funded by
7 institutional support of the Department of Cardiology at Bern University Hospital, Bern, Switzerland, which
8 had no role in the data analysis, interpretation, or writing of the report. The corresponding and first and third
9 authors (MV, RP, and OE) had full access to the data and had final responsibility for the decision to submit
10 for publication.

1 Results

2 We screened 19,454 unique citations. Of these, 601 were judged potentially eligible during screening
3 of titles and abstracts, and 20 deemed eligible after full text review (**Figure 1**). IPD were sought and obtained
4 for all 20 studies, which, therefore, contributed to the IPD meta-analysis. The **web-appendix** describes trial
5 characteristics, patient populations, and the definitions used for outcomes (**Tables S1-S3**). Overall, we
6 obtained data for 26,616 participants; 14,070 (53%) randomized to DES and 12,546 (47%) randomized to
7 BMS. Baseline clinical characteristics were largely balanced between the two study groups (**Table 1**).
8 Slightly more males were allocated to DES and patients randomized to BMS tended to receive stents with
9 larger diameters and shorter lengths. Supplementary **Table S4** provides details on the risk of bias
10 assessment. Overall, trials were judged at low risk of bias, although blinding of patients and performing
11 physicians was done only in four trials.

12 Most patients received thin-strut stents, which, however, were less frequently implanted among
13 those assigned to DES than BMS (79.7% vs. 85.3%, $p<0.001$). In the DES group, the following devices were
14 implanted in more than 90% of patients: everolimus-eluting stents (Xience in 4,064 or 28.9%, Promus in
15 2,866 or 20.4%, and Synergy in 596 or 4.2%), zotarolimus-eluting stents (Endeavor in 1,932 or 13.7%, and
16 Resolute in 475 or 3.4%), biolimus-eluting stents (Biofreedom in 1,221 or 8.7%, Nobori in 765 or 5.68%, and
17 BioMatrix in 655 or 4.86%), and sirolimus-eluting stents (Ultimaster in 375 or 2.78%) (**Table S5**). Early-
18 generation DES were implanted in a small proportion of patients (1.4%). In the BMS group, the following
19 devices were implanted in about 80% of patients: Driver in 3,076 or 24.5%, Vision in 2,742 or 21.9%,
20 Gazelle in 1,793 or 14.3%, Integrity in 914 or 7.3%, Libertè in 778 or 6.2%, Pro-kinetic in 768 or 6.1%,
21 Omega/Rebel in 604 or 4.8%. Duration of dual antiplatelet therapy was on average 50 days longer after DES
22 than BMS (302 ± 179 vs. 253 ± 176 days, $p<0.001$).

23 The maximum length of follow-up ranged from 1 to 6 years with a duration of follow-up of 2 years or
24 more in 14 trials and up to, or more than, 5 years in 6 trials. The mean (\pm standard deviation) follow-up time
25 was 3.2 ± 1.8 years (median, 2.1; interquartile range, 1.9 to 4.9). Ten trials reported sponsorship to be
26 independent from industry (**Table S1**).

27 At longest available follow-up, the risk of the primary outcome of cardiac death or MI was
28 significantly lower among patients randomized to DES than BMS (14.49% vs. 16.65%, respectively; HR
29 0.84, 95%CI 0.78 to 0.90, $P<0.001$), yielding a number needed to treat for benefit (NNTB) in the range of 46
30 (**Table 2, Figure 2**). We found evidence that DES were associated with a reduced risk of MI as compared
31 with BMS (HR 0.79, 95%CI 0.71 to 0.88, $P<0.001$), whereas the effect of DES vs. BMS on cardiac fatality

1 rates was weaker and did not reach conventional levels of statistical significance (HR 0.89, 95%CI 0.78 to
2 1.01, $p=0.075$). We found no difference between DES and BMS in terms of all-cause death (HR 0.96,
3 95%CI 0.88 to 1.05, $P=0.358$). As compared with BMS, patients assigned to DES had a reduced risk of
4 definite stent thrombosis (HR 0.63, 95%CI 0.50 to 0.80, $P<0.001$) and TVR (HR 0.55, 95%CI 0.50 to 0.60,
5 $P<0.001$). Risk estimates for primary and secondary outcomes at 5-year follow-up were consistent with
6 those observed at time of longest follow-up (**Table 2**).

7 Results of the landmark analysis are reported in **Figure 3** and Kaplan-Meier curves during different
8 time intervals are shown in the **web-appendix (Figure S1)**. For the primary outcome, there was significant
9 heterogeneity in the treatment effect of DES vs. BMS before and after 1 year ($P_{\text{int}}<0.001$). DES compared
10 with BMS reduced the risk of cardiac death or MI during the first year after implantation (HR 0.74, 95%CI
11 0.67 to 0.81), but not beyond 365 days (HR 1.04, 95%CI 0.92 to 1.18). During the first year after PCI, DES
12 use was also associated with a reduced risk of cardiac death (HR 0.82, 95%CI 0.70 to 0.96) and MI (HR
13 0.69, 95%CI 0.62 to 0.78) when separately appraised, with no detectable treatment effect beyond 1-year
14 (HR 1.03, 95%CI 0.84 to 1.26; $P_{\text{int}}=0.079$ and HR 1.06, 95%CI 0.93 to 1.22; $P_{\text{int}}<0.001$, respectively). A
15 similar pattern was found for other secondary outcomes, such as stent thrombosis and TVR. In a further
16 analysis with two landmark points, DES remained associated to consistently lower risks of the primary
17 outcome, MI, ST, and TVR between 0 and 30 days as well as between 31 and 365 days (**Table S6**).

18 The effect of DES versus BMS on the rate of the primary outcome at longest available follow-up was
19 consistent across subgroups, including age, gender, clinical presentation, number and size of implanted
20 stents, with the only exception for the target-vessel location ($P_{\text{int}}=0.010$) (**Figure 4**). There was strong
21 evidence that DES lowers the risk of cardiac death or MI among patients undergoing stent implantation in the
22 left anterior descending artery (HR 0.76, 95%CI 0.68 to 0.85, $P<0.001$). There was weak evidence of an
23 effect in patients undergoing treatment in other coronary vessels (HR 0.92, 95%CI 0.82 to 1.02, $P=0.112$).

24 We did not find clinically important heterogeneity in all meta-analyses, although there was a
25 moderate heterogeneity for MI at longest follow-up, resulting in non-significant prediction intervals (**Figure**
26 **S2**).

27

28 **Sensitivity analyses**

29 The main results of the IPD meta-analysis remained entirely consistent at the two-stage random effects
30 approach (**Table S7, Figure S2-S4**) and one-stage fixed effect approach (**Table S8**). Results for primary and
31 secondary outcomes remained unchanged after excluding patients who were randomized to BMS and

1 received thick-strut stents and after excluding patients who randomized to DES and received early-
2 generation devices (**Tables S9-S10**). In a sensitivity analysis, we fitted a model including both within- and
3 across-studies interactions between treatment and target-vessel location. Results were similar (P-int =0.018)
4 to the ones obtained by the model including only a within-studies interaction.

1 **Discussion**

2 Using the totality of available data from randomized trials comparing new-generation DES with BMS among
3 26,616 participants undergoing PCI, our collaborative IPD meta-analysis provides strong evidence that DES
4 reduce the risk of cardiac death or MI compared with BMS at a mean follow-up time of 3.2 years or up to 5
5 years. This benefit was mainly due to a decreased risk of MI with DES and a non-significant reduction of
6 cardiac death as compared with BMS. The use of DES was also associated with a significantly lower risk of
7 stent thrombosis and TVR at longest available follow-up or at 5 years.

8
9 Introduced in 2002, DES represented a paradigm shift in the treatment of patients undergoing PCI owing to a
10 convincing reduction in the need for repeat revascularization compared with BMS. However, after initial use
11 and evaluation in clinical trials, safety concerns were raised due to excess of very late (>1 year) thrombotic
12 events with early-generation devices.

13 The transition from early- to new-generation DES, which are vastly represented in this study (>98% of
14 participants), entailed a broad range of refinements, including the use of lower antiproliferative drug loads,
15 the omission of paclitaxel as antiproliferative agent, thinner metallic stent struts, and more biocompatible
16 durable or biodegradable polymers as well as polymer-free stents. Nevertheless, a lingering controversy
17 exists as to whether the introduction of new-generation DES impacts on more prognostically relevant
18 endpoints, such as death or MI.

19 In the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) trial, which
20 included 1,498 patients with acute myocardial infarction, there was a significant reduction in the risk of all-
21 cause death with DES compared with BMS at 5-year follow-up.¹⁶ Although this observation was mainly
22 related to a decrease in non-cardiac fatalities, it has been speculated that the prevention of stent thrombosis
23 and repeat revascularization among patients randomized to DES might have led to less rehospitalization and
24 other complications including infections and sepsis, which were the second major cause of non-cardiac
25 death in the trial.¹⁶ Conversely, the larger Norwegian Coronary Stent Trial (NORSTENT), which included
26 9,013 patients, did not find evidence of a benefit of DES in terms of all-cause as well as cardiac death or MI
27 rates.¹⁷ Yet, there was a significant 36% risk reduction for definite stent thrombosis with DES as compared to
28 BMS. Fueled by greater safety perceptions and lower costs, BMS continue to be implanted in 20% of
29 contemporary PCI procedures involving patients aged 65 years or older.⁷ While the use of BMS is no longer
30 recommended across several guidelines of the European Society of Cardiology,¹⁸ no such position is
31 endorsed by ACC/AHA guidelines, which, however, were published in 2011.¹⁹

1 Our IPD meta-analysis provides robust evidence that the use of DES reduced by 21% the hazard of MI
2 compared with BMS. This finding is relevant as only two out of 20 trials have individually reported a
3 difference in MI between DES and BMS.^{20,21} Interestingly, both of these studies recruited mainly²⁰ or
4 exclusively²¹ patients deemed at high bleeding risk and mandated 1-month duration of dual antiplatelet
5 therapy irrespective of stent types. Hence, the argument that DES implantation lowers MI rates because of
6 concomitant longer duration of dual antiplatelet therapy seems invalid. The decreased hazard of MI with DES
7 is biologically plausible given the concurrent reductions in stent thrombosis and TVR. The clinical correlate of
8 stent thrombosis is death or MI in more than 90% of cases²² and roughly one third of patients with in-stent
9 restenosis requiring repeat revascularization in a target-vessel is admitted with acute coronary syndrome.²³
10 Furthermore, restenosis after coronary stenting has been associated with a higher risk of mortality in cohorts
11 undergoing angiographic surveillance.²⁴ Even elective and uncomplicated revascularization in the target-
12 vessel is associated with an increased risk of mortality, partly related to a higher risk of myocardial infarction
13 following repeat revascularization procedures.²⁵

14 Yet, we did not find evidence that the use of DES affects all-cause mortality whereas cardiac fatalities were
15 only marginally and not significantly lower with DES at longest available follow-up.

16 In our IPD analysis, 2,027 fatal events were observed of which less than 50% (997 or 49.2%) were from
17 cardiac causes. Consequently, the predominant mode of death in patients undergoing PCI, particularly
18 during the long-term follow-up, was non-cardiac, which is unlikely to be prevented by the type of coronary
19 stent. These findings align well with other registry data showing a pronounced temporal switch from
20 predominantly cardiac to predominantly non-cardiac causes of death after PCI in the past two decades.²⁶

21 There was evidence for time-dependent treatment effects, with DES being associated with lower risks of
22 cardiac death during the first year followed by a null effect in the subsequent years. While interaction testing
23 provided only borderline significance, the time-dependent distribution of the treatment benefit observed for
24 cardiac mortality was highly consistent with those observed for other safety endpoints, including MI or stent
25 thrombosis and even TVR, which was numerically but not significantly reduced from the second year
26 onwards with DES. Hence, it remains plausible that an early cardiac mortality benefit, likely arisen by MI, ST
27 and even TVR risk mitigation by DES within the first year, diminishes over time due to non-stent related
28 fatalities.

29 The observation that beneficial effects of DES on safety endpoints, including MI and ST, accrued exclusively
30 within the first year after treatment and consistently within 30 days or in between 30 days and 1 year with no
31 signal of further incremental benefit or loss thereafter is remarkable and deserves attention. First, it suggests

1 that contemporary DES technology is less prone to thrombotic events early (i.e. within 30 days) after stent
2 implantation and confirms the lower risk of non-fatal ischemic events associated to lower intimal hyperplasia.
3 Second, it provides reassuring evidence that the long-term (beyond 1 year) safety issues, in terms of
4 increased MI and ST rates observed with early generation DES as compared to BMS, has been resolved.
5 Third, it shows that contemporary DES technology outperforms the safety and efficacy profile of BMS within
6 the first year after implantation, without further comparative improvements being visible in the subsequent
7 years. Hence, while BMS should no longer be considered the gold standard for safety, the observation that
8 the risks of death or MI beyond 1 year after implantation do not differ between current generation DES as
9 compared to BMS carries relevant clinical and pathophysiological implications and suggests that the focus of
10 future technology should target clinical outcome improvements not only within but also beyond 1-year after
11 stent implantation.

12

13 A further strength of this IPD meta-analysis was the opportunity to explore the treatment effect of DES vs.
14 BMS across several subgroups. We did not find any evidence of interaction between the primary outcome
15 (cardiac death or MI) and any patient or lesion characteristic, except for target-vessel location. The reduction
16 of the primary outcome with DES over BMS was more evident among patients who underwent PCI of the left
17 anterior descending artery as opposed to other locations. As the myocardial territory supplied by the left
18 anterior descending artery is larger than other vessels (45-55% of the left ventricle), it is likely that this
19 patient population derived a greater benefit from the prevention of restenosis and stent thrombosis with DES
20 compared with BMS.

21

22 The results of this study should be interpreted in view of several limitations. First, the study has limitations
23 inherent in patient-level, pooled analyses reflecting the shortcomings of the original studies. Second,
24 although 90% of patients received a limited number of DES with everolimus-eluting stents being implanted in
25 more than 50% of cases, a mixture of DES was used in the experimental arm. Third, a minority of patients
26 received early-generation DES that are associated with lower safety and efficacy than new-generation DES
27 and are no longer used in clinical practice. However, after the exclusion of these patients, results remained
28 unchanged. Fourth, although there was no signal of difference between DES and BMS beyond 1 year, the
29 mean follow-up in our IPD analysis was about 3 years and therefore longer duration follow-up is needed to
30 confirm the durability of the benefit observed here at a medium-term time point. Fifth, the effect of stent
31 selection on the MI type could not be assessed, as many of the included studies failed to collect this

1 information. Finally, we did not adjust or account for post-randomization covariates, such as actual duration
2 of dual antiplatelet therapy, to avoid violating the principle of randomization. However, several trials are
3 under way to address the efficacy and safety of abbreviated antiplatelet regimens after contemporary PCI.²⁷

4

5 In conclusion, our collaborative meta-analysis based on the totality of available randomized data showed that
6 the use of new generation DES rather than BMS, is associated with a sustained reduction in the risk of
7 cardiac death or myocardial infarction, with time-dependent treatment effects characterized by a lower risk of
8 the composite endpoint accrued during the first year without an off-setting effect during the subsequent
9 years.

10

1 **Research in context**

2 **Evidence before this study**

3 We searched PubMed, EMBASE, and three websites (www.tctmd.com, www.escardio.org,
4 www.cardiosource.com) up to December 19th, 2017, to identify randomized trials comparing new-generation
5 drug-eluting stents (DES) with bare-metal stents (BMS) in patients undergoing percutaneous coronary
6 intervention (PCI). We used search terms “stents”, “drug-eluting stents”, “percutaneous coronary
7 intervention” and “random*”. Trials were included if patients underwent PCI with the use of new-generation
8 DES in at least 90% of the population allocated to the experimental arm. Evidence to support the use of new-
9 generation DES for PCI is mainly based on trials showing the superiority of newer DES in comparison to
10 earlier generation DES or the non-inferiority between different types of new-generation DES. In contrast,
11 evidence related to head-to-head comparisons between new-generation DES and BMS is more fragmented
12 and, so far, it remains unclear whether new-generation DES improve clinical outcomes, such as myocardial
13 infarction or cardiac death, as opposed to BMS. Only two separate studies have observed a reduction in the
14 risk of myocardial infarction in favor of new-generation DES compared with BMS. Yet, almost all trials
15 included repeat revascularization procedures in their primary endpoint and therefore provided imprecise
16 estimates for less common but more prognostically relevant adverse events, such as myocardial infarction or
17 cardiac death. After electronic search, we found 20 trials eligible for the study for which we requested and
18 obtained IPD.

19 **Added value of this study**

20 In this IPD meta-analysis of randomized trials, we found that new-generation DES reduced the risk of cardiac
21 death or myocardial infarction as compared with BMS. There was also strong evidence for a reduction of
22 myocardial infarction, stent thrombosis and target-vessel revascularization, whereas cardiac death was
23 numerically lower with DES without reaching formal statistical significance after a mean follow-up of 3.2 ± 1.8
24 years. By further investigating the treatment effects across different time-periods, we found that new-
25 generation DES reduced adverse events including cardiac death within 1-year with no signal of further
26 incremental benefit or loss thereafter. At pre-defined subgroup analysis, we identified a stronger reduction in
27 cardiac death or myocardial infarction with DES instead of BMS for patients who received stents in the left
28 anterior descending artery, with positive interaction testing.

29 **Implications of all the available evidence**

30 Our study provides evidence that the use of new-generation DES instead of BMS is associated to improved
31 outcomes as compared with BMS with reductions in both efficacy and safety parameters. The benefit of DES

1 accrues early (i.e. within 1 year) after PCI and is maintained over longer term follow-up. The meta-analysis
2 provides strong evidence that BMS should no longer be considered the gold standard for safety and
3 questions their use in current clinical practice.

- 1 **Contributors**
- 2 *Raffaele Piccolo*, Designed the study, analysed and interpreted data, drafted and approved the final
- 3 manuscript.
- 4 *Kaare H. Bonnaa*, Interpreted data, revised and approved the final version of the manuscript.
- 5 *Orestis Efthimiou*, Designed the study, analysed and interpreted data, revised and approved the final
- 6 manuscript.
- 7 *Olivier Varenne*, Interpreted data, revised and approved the final version of the manuscript.
- 8 *Andrea Baldo*, Designed the study, analysed and interpreted data, revised and approved the final
- 9 manuscript.
- 10 *Philip Urban*, Interpreted data, revised and approved the final version of the manuscript.
- 11 *Christoph Kaiser*, Interpreted data, revised and approved the final version of the manuscript.
- 12 *Wouter Remkes*, Interpreted data, revised and approved the final version of the manuscript.
- 13 *Lorenz Råber*, Interpreted data, revised and approved the final version of the manuscript.
- 14 *Adam de Belder*, Interpreted data, revised and approved the final version of the manuscript.
- 15 *Arnoud W.J. van't Hof*, Interpreted data, revised and approved the final version of the manuscript.
- 16 *Goran Stankovic*, Interpreted data, revised and approved the final version of the manuscript.
- 17 *Pedro A. Lemos*, Interpreted data, revised and approved the final version of the manuscript.
- 18 *Tom Wilsgaard*, Interpreted data, revised and approved the final version of the manuscript.
- 19 *Jörg Reifart*, Interpreted data, revised and approved the final version of the manuscript.
- 20 *Alfredo E. Rodriguez*, Interpreted data, revised and approved the final version of the manuscript.
- 21 *Expedito E. Ribeiro*, Interpreted data, revised and approved the final version of the manuscript.
- 22 *Patrick W.J.C. Serruys*, Interpreted data, revised and approved the final version of the manuscript.
- 23 *Alex Abizaid*, Interpreted data, revised and approved the final version of the manuscript.
- 24 *Manel Sabaté*, Interpreted data, revised and approved the final version of the manuscript.
- 25 *Robert A. Byrne*, Interpreted data, revised and approved the final version of the manuscript.
- 26 *Jose M. de la Torre Hernandez*, Interpreted data, revised and approved the final version of the manuscript.
- 27 *William Wijns*, Interpreted data, revised and approved the final version of the manuscript.
- 28 *Peter Jüni*, Interpreted data, revised and approved the final version of the manuscript.
- 29 *Stephan Windecker*, Interpreted data, revised and approved the final version of the manuscript.
- 30 *Marco Valgimigli*, Conceived, designed and interpreted the study, drafted the manuscript, revised and
- 31 approved the final manuscript.

1 **Financial Disclosures**

2 *Dr. Varenne* reports personal fees from Boston Scientific, personal fees from Abbott Vascular, personal fees
3 from Astra Zeneca, personal fees from Biotronik, personal fees from Servier, non-financial support from
4 Biosensors, outside the submitted work;

5 *Dr. Urban* reports and Consultant to Biosensors, a stent manufacturing company.

6 *Dr. Raeber* reports personal fees from Abbott Vascular, personal fees from Amgen, personal fees from Astra
7 Zeneca, personal fees from Biotronik, personal fees from CLS Bhering, personal fees from Sanofi, personal
8 fees from Regeneron, grants from Abbott Vascular, grants from Heartflow, grants from Regenron, grants
9 from Sanofi, outside the submitted work;

10 *Dr. Byrne* reports personal fees from B. Braun Melsungen AG, personal fees from Biotronik, grants and
11 personal fees from Boston Scientific, grants from Celonova Biosciencers, personal fees from Micell
12 Technologies, outside the submitted work;

13 *Dr. Serruys* reports personal fees from Abbott, personal fees from Biosensors, personal fees from
14 Cardialysis, personal fees from Medtronic, personal fees from Sinomedical Sciences, personal fees from
15 Philips/Volcano, personal fees from Xeltis, personal fees from HeartFlow, outside the submitted work; and

16 *Dr. Serruys* reports personal consultancy fees from Abbott Laboratories, Biosensors, Cardialysis, Medtronic,
17 Sino Medical Sciences Technology, Philips/Volcano, Xeltis, Heartflow.

18 *Dr. van 't Hof* reports grants from Medtronic, during the conduct of the study;

19 *Dr. De la Torre Hernandez* reports and Unrestricted grants for research from Amgen, Biotronik, Abbott,
20 Bristol-Myers-Squibb; Payments for advisory from Medtronic, Boston scientific, Astra-Zeneca, Daichy.

21 *Dr. Wijns* reports grants and personal fees from Biotronik , grants from Medtronic, grants from Terumo,
22 grants from Mi-Cell, grants from Micro-Port, during the conduct of the study; and Medical Advisor Rede
23 Optimus Research, co-founder Argonauts, an innovation facilitator.

24 *Dr. Sabaté* reports to be consultant to Abbott Vascular, a stent manufacturing company.

25 *Peter Jüni* serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik,
26 Biosensors, St. Jude Medical and The Medicines Company.

27 *Dr. Windecker* reports grants from Amgen, grants from Abbott, grants from Boston Scientific, grants from
28 Biotronik, grants from Medtronic, grants from Edwards Lifesciences, grants from St Jude, grants from
29 Terumo, grants from Bayer, outside the submitted work;

30 *Dr. Valgimigli* reports grants and personal fees from Abbott, personal fees from Chiesi, personal fees from
31 Bayer, personal fees from Daiichi Sankyo, personal fees from Amgen, grants and personal fees from

- 1 Terumo, personal fees from Alvimedica, grants from Medicure, grants and personal fees from Astrazeneca,
- 2 personal fees from Biosensors, personal fees from Idorsia, outside the submitted work.
- 3

REFERENCES

- 1
- 2 1 Piccolo R, Giustino G, Mehran R, Windecker S. Stable coronary artery disease: Revascularisation
3 and invasive strategies. *Lancet* 2015; **386**: 702–13.
- 4 2 Valgimigli M, Percoco G, Malagutti P, *et al.* Tirofiban and sirolimus-eluting stent vs abciximab and
5 bare-metal stent for acute myocardial infarction: a randomized trial. *JAMA* 2005; **293**: 2109–17.
- 6 3 Valgimigli M, Campo G, Percoco G, *et al.* Comparison of angioplasty with infusion of tirofiban or
7 abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial
8 infarction: the MULTISTRATEGY randomized trial. *JAMA* 2008; **299**: 1788–99.
- 9 4 Valgimigli M, Tebaldi M, Borghesi M, *et al.* Two-year outcomes after first- or second-generation drug-
10 eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary
11 intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet
12 Treatment. *JACC Cardiovasc Interv* 2014; **7**: 20–8.
- 13 5 Palmerini T, Biondi-Zoccai G, Della Riva D, *et al.* Stent thrombosis with drug-eluting and bare-metal
14 stents: evidence from a comprehensive network meta-analysis. *Lancet* 2012; **379**: 1393–402.
- 15 6 Kang SH, Chae IH, Park JJ, *et al.* Stent Thrombosis With Drug-Eluting Stents and Bioresorbable
16 Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials. *JACC Cardiovasc Interv* 2016; **9**:
17 1203–12.
- 18 7 Rymer JA, Harrison RW, Dai D, *et al.* Trends in Bare-Metal Stent Use in the United States in Patients
19 Aged ≥65 Years (from the CathPCI Registry). *Am J Cardiol* 2016; **118**: 959–66.
- 20 8 Stewart LA, Clarke M, Rovers M, *et al.* Preferred Reporting Items for Systematic Review and Meta-
21 Analyses of individual participant data: the PRISMA-IPD Statement. *JAMA* 2015; **313**: 1657–65.
- 22 9 Valgimigli M, Sabaté M, Kaiser C, *et al.* Effects of cobalt-chromium everolimus eluting stents or bare
23 metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. *BMJ* 2014; **349**:
24 g6427.
- 25 10 Debray TPA, Moons KGM, van Valkenhoef G, *et al.* Get real in individual participant data (IPD) meta-
26 analysis: a review of the methodology. *Res Synth Methods* 2015; **6**: 293–309.
- 27 11 Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary
28 outcome. *Stat Med* 2001; **20**: 3875–89.
- 29 12 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; **21**: 1539–
30 58.
- 31 13 IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in

1 meta-analysis. *BMJ Open* 2016; **6**: e010247.

2 14 Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003; **326**:
3 219.

4 15 Hua H, Burke DL, Crowther MJ, Ensor J, Tudur Smith C, Riley RD. One-stage individual participant
5 data meta-analysis models: estimation of treatment-covariate interactions must avoid ecological bias
6 by separating out within-trial and across-trial information. *Stat Med* 2017; **36**: 772–89.

7 16 Sabaté M, Brugaletta S, Cequier A, *et al.* Clinical outcomes in patients with ST-segment elevation
8 myocardial infarction treated with everolimus-eluting stents versus bare-metal stents
9 (EXAMINATION): 5-year results of a randomised trial. *Lancet* 2016; **387**: 357–66.

10 17 Bønaa KH, Mannsverk J, Wiseth R, *et al.* Drug-Eluting or Bare-Metal Stents for Coronary Artery
11 Disease. *N Engl J Med* 2016; **375**: 1242–52.

12 18 Neumann F-J, Sousa-Uva M, Ahlsson A, *et al.* 2018 ESC/EACTS Guidelines on myocardial
13 revascularization. *Eur Heart J* 2018; **40**: 87–165.

14 19 Levine GN, Bates ER, Blankenship JC, *et al.* 2011 ACCF/AHA/SCAI Guideline for Percutaneous
15 Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart
16 Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and
17 Interventions. *J Am Coll Cardiol* 2011; **58**: e44-122.

18 20 Valgimigli M, Patialiakas A, Thury A, *et al.* Zotarolimus-eluting versus bare-metal stents in uncertain
19 drug-eluting stent candidates. *J Am Coll Cardiol* 2015; **65**: 805–15.

20 21 Urban P, Meredith IT, Abizaid A, *et al.* Polymer-free Drug-Coated Coronary Stents in Patients at High
21 Bleeding Risk. *N Engl J Med* 2015; **373**: 2038–47.

22 22 Windecker S, Meier B. Late coronary stent thrombosis. *Circulation* 2007; **116**: 1952–65.

23 23 Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a
24 benign clinical entity. *Am Heart J* 2006; **151**: 1260–4.

25 24 Cassese S, Byrne RA, Schulz S, *et al.* Prognostic role of restenosis in 10 004 patients undergoing
26 routine control angiography after coronary stenting. *Eur Heart J* 2015; **36**: 94–9.

27 25 Palmerini T, Della Riva D, Biondi-Zoccai G, *et al.* Mortality Following Nonemergent, Uncomplicated
28 Target Lesion Revascularization After Percutaneous Coronary Intervention: An Individual Patient
29 Data Pooled Analysis of 21 Randomized Trials and 32,524 Patients. *JACC Cardiovasc Interv* 2018;
30 **11**: 892–902.

31 26 Spoon DB, Psaltis PJ, Singh M, *et al.* Trends in cause of death after percutaneous coronary

- 1 intervention. *Circulation* 2014; **129**: 1286–94.
- 2 27 Frigoli E, Smits P, Vranckx P, *et al.* Design and rationale of the Management of High Bleeding Risk
- 3 Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus
- 4 Standard DAPT Regimen (MASTER DAPT) Study. *Am Heart J* 2018; **209**: 97–105.

1 **FIGURES LEGEND**

2

3 **Figure 1.** PRISMA Flow Diagram for the Systematic Review.

4

5 **Figure 2.** Kaplan-Meier curves at longest follow-up for cardiac death or myocardial infarction (**Panel A**), all-
6 cause death (**Panel B**), cardiac death (**Panel C**), myocardial infarction (**Panel D**), target-vessel
7 revascularization (**Panel D**), and definite stent thrombosis (**Panel E**). Red lines represent bare-metal stents
8 and blue lines represent drug-eluting stents.

9

10 **Figure 3.** Landmark analysis. P values for interaction are between hazard ratios (HR) with 95% confidence
11 intervals (95%CI) calculated from 0 to 365 days and after 365 days.

12

13 **Figure 4.** Subgroup analysis and meta-regressions for the primary outcome. BMS: bare-metal stents. CAD:
14 coronary artery disease. ACS: acute coronary syndrome. BMS: bare-metal stents. CAD: coronary artery
15 disease. DES: drug-eluting stents. LAD: left anterior descending artery. 7: PCI percutaneous coronary
16 intervention.

17

1 **Table 1.** Baseline and procedural characteristics.

	Drug-eluting stents (N=14,070)	Bare-metal stents (N=12,546)	P- value
Age, years	n = 14067, 65.7±12.3	n = 12541, 66.3±12.4	0.458
Male	n = 14069, 10542 (74.9%)	n = 12543, 9269 (73.9%)	0.067
Smokers	n = 13654, 4277 (31.3%)	n = 12149, 3809 (31.4%)	0.092
Hypertension	n = 14029, 8259 (58.9%)	n = 12500, 7324 (58.6%)	0.156
Hyperlipidemia	n = 13731, 7904 (57.6%)	n = 12208, 6974 (57.1%)	0.208
Diabetes	n = 14046, 2740 (19.5%)	n = 12525, 2344 (18.7%)	0.069
Insulin-treated	n = 2677, 446 (16.7%)	n = 2323, 378 (16.3%)	0.426
Previous MI	n = 14025, 2143 (15.3%)	n = 12505, 2007 (16.0%)	0.548
Previous PCI	n = 9950, 1901 (19.1%)	n = 8507, 1806 (21.2%)	0.074
Previous CABG	n = 14060, 905 (6.4%)	n = 12541, 1004 (8.0%)	0.605
Indication to PCI			
Stable CAD	n = 13927, 4047 (29.1%)	n = 12408, 3644 (29.4%)	0.907
Unstable angina	n = 14012, 1959 (14.0%)	n = 12478, 1871 (15.0%)	0.956
Non-ST-elevation MI	n = 13975, 3479 (24.9%)	n = 12462, 3164 (25.4%)	0.636
ST-elevation MI	n = 13922, 4105 (29.5%)	n = 12406, 3427 (27.6%)	0.522
Gp IIb/IIIa receptor inhibitors	n = 12344, 2781 (22.5%)	n = 11020, 2378 (21.6%)	0.420
Multivessel disease	n = 13517, 5837 (43.2%)	n = 11993, 4968 (41.4%)	0.239
Number of implanted stents	n = 14039, 1.6±1.0	n = 12507, 1.6±1.0	0.391
Total stent length, mm	n = 13956, 28.4±19.5	n = 12424, 26.9±18.2	<0.001
Mean stent diameter, mm	n = 13956, 3.3±0.5	n = 12421, 3.3±0.6	<0.001
Overlapping stent	n = 13403, 2395 (17.9%)	n = 11877, 2152 (18.1%)	0.201
Number of stented segments	n = 14052,	n = 12524,	0.088
0	5 (0.0%)	5 (0.0%)	
1	10297 (73.3%)	9231 (73.7%)	
2	2758 (19.6%)	2480 (19.8%)	
3	751 (5.3%)	608 (4.9%)	
4	188 (1.3%)	141 (1.1%)	
5	40 (0.3%)	52 (0.4%)	
6	10 (0.1%)	6 (0.0%)	
7	3 (0.0%)	1 (0.0%)	
Target-vessel location			
Left main artery	n = 13968, 1022 (7.3%)	n = 12463, 591 (4.7%)	0.499
Left anterior descending artery	n = 13968, 6476 (46.4%)	n = 12463, 5805 (46.6%)	0.859
Left circumflex artery	n = 13968, 4047 (29.0%)	n = 12463, 3433 (27.5%)	0.51
Right coronary artery	n = 13968, 5260 (37.7%)	n = 12462, 4674 (37.5%)	0.279
Thin-strut stent (<100 µm)	n = 14046, 11198 (79.7%)	n = 12526, 10681 (85.3%)	<0.001
Type of P2Y ₁₂ receptor inhibitor	n = 12123,	n = 10814,	0.919
None	1 (0.0%)	3 (0.0%)	

Clopidogrel	10726 (84.8%)	10217 (90.0%)	
Ticagrelor	89 (0.7%)	63 (0.6%)	
Prasugrel	1837 (14.5%)	1069 (9.4%)	
Duration of DAPT, days	n = 12200, 291.7±180.4	n = 10805, 244.2±175.9	<0.001

All data are shown at patient-level. CABG: coronary artery bypass grafting; CAD: coronary artery disease; DAPT: dual antiplatelet therapy; Gp: glycoprotein.; MI: myocardial infarction.

1 **Table 2.** Results of one-stage meta-analysis.

	Drug-eluting stents (N=14,070)	Bare-metal stents (N=12,546)	HR (95%CI)	P-value	τ
At longest available follow-up					
Cardiac death or MI	1371 (14.49)	1472 (16.65)	0.84 (0.78 to 0.90)	<0.001	0.003
All-cause death	1031 (10.97)	996 (11.98)	0.96 (0.88 to 1.05)	0.358	0.004
Cardiac death	494 (4.76)	503 (5.75)	0.89 (0.78 to 1.01)	0.075	0.003
Myocardial infarction	1020 (11.65)	1124 (13.58)	0.79 (0.71 to 0.88)	<0.001	0.070
Target-vessel revascularization	920 (9.56)	1448 (14.95)	0.55 (0.50 to 0.60)	<0.001	0.003
Definite stent thrombosis	125 (1.20)	173 (1.70)	0.63 (0.50 to 0.80)	<0.001	0.008
At 5-year follow-up					
Cardiac death or MI	1345 (12.48)	1446 (14.16)	0.83 (0.78 to 0.90)	<0.001	0.003
All-cause death	1013 (9.82)	974 (10.44)	0.95 (0.88 to 1.05)	0.400	0.004
Cardiac death	490 (4.55)	492 (4.84)	0.90 (0.79 to 1.03)	0.116	0.003
Myocardial infarction	994 (9.56)	1099 (11.04)	0.78 (0.72 to 0.88)	<0.001	0.056
Target-vessel revascularization	904 (8.38)	1436 (13.40)	0.54 (0.50 to 0.59)	<0.001	0.003
Definite stent thrombosis	123 (1.09)	171 (1.58)	0.63 (0.50 to 0.80)	<0.001	0.008
At 1-year follow-up					
Cardiac death or MI	829 (5.95)	989 (7.96)	0.74 (0.67 to 0.81)	<0.001	0.003
All-cause death	499 (3.58)	495 (3.98)	0.94 (0.81 to 1.04)	0.197	0.003
Cardiac death	301 (2.20)	331 (2.72)	0.82 (0.70 to 0.96)	0.016	0.003
Myocardial infarction	591 (4.25)	746 (6.03)	0.69 (0.62 to 0.78)	<0.001	0.070
Target-vessel revascularization	547 (3.98)	1073 (8.77)	0.43 (0.39 to 0.48)	<0.001	0.015
Definite stent thrombosis	83 (0.60)	137 (1.11)	0.52 (0.40 to 0.69)	<0.001	0.008

2 BMS: bare-metal stents. DES: drug-eluting stents. MI: myocardial infarction.

Figure 1. PRISMA Flow Diagram for the Systematic Review.




Figure 2. Kaplan-Meier curves at longest follow-up.




Figure 3. Landmark analysis.




Figure 4. Subgroup analysis and meta-regressions for the primary outcome.

